Last updated: October 25, 2023
Sponsor: Heron Therapeutics
Overall Status: Completed
Phase
4
Condition
Pain
Acute Pain
Chronic Pain
Treatment
Ibuprofen
HTX-011
Bupivacaine Hydrochloride
Clinical Study ID
NCT06109415
HTX-011-401 (Cohort 1)
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Has American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.
- Is scheduled to undergo a unilateral Total Shoulder Arthroplasty.
Exclusion
Exclusion Criteria:
- Is undergoing a revision surgery.
- Has a known or suspected history of hypersensitivity or clinically significantidiosyncratic reaction to bupivacaine (or other local anesthetics), NSAIDs,acetaminophen, oxycodone, morphine, or hydromorphone.
- History of severe allergic reaction to aspirin or other NSAIDs, or known history ofsevere gastrointestinal adverse reactions associated with NSAID use.
- Has taken meloxicam within 10 days prior to the scheduled surgery, or any NSAID within 24 hours prior to the scheduled surgery, with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection.
- Opioid use for most days within the last 3 months prior to Screening in the opinion ofthe Investigator.
- Has been administered immediate-release bupivacaine HCl within 5 days prior to thescheduled surgery, or a modified-release bupivacaine product within 14 days prior tothe scheduled surgery.
- Has initiated treatment with any of the following medications within 1 month prior tostudy drug administration: selective serotonin reuptake inhibitors, selectivenorepinephrine reuptake inhibitors, gabapentin, pregabalin, duloxetine, orcyclooxygenase-2 inhibitors.
- Has been administered systemic steroids within 5 half-lives or 10 days prior to thescheduled surgery (whichever is longer).
- Has a known or suspected history of drug abuse, a positive drug screen (except forcannabinoids) on the day of surgery, or a history of alcohol abuse within the past 5years.
- Suspected or confirmed active coronavirus disease 2019 (COVID-19) infection.
- Had a malignancy in the last year, with the exception of nonmetastatic basal cell orsquamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
- Has undergone 3 or more surgeries within 12 months, other than for diagnosticprocedures (eg, colonoscopy).
- Has a body mass index (BMI) >40 kg/m2.
Study Design
Total Participants: 30
Treatment Group(s): 5
Primary Treatment: Ibuprofen
Phase: 4
Study Start date:
October 20, 2021
Estimated Completion Date:
July 29, 2022
Connect with a study center
Woodland International Research Group, LLC
Little Rock, Arkansas 72211
United StatesSite Not Available
Center for Orthopaedic Reconstruction and Excellence
Jenks, Oklahoma 74037
United StatesSite Not Available
First Surgical Hospital
Bellaire, Texas 77401
United StatesSite Not Available
Legent Orthopedic Hospital
Carrollton, Texas 75006
United StatesSite Not Available
JBR Clinical Research
Salt Lake City, Utah 84107
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.